but the companies "strategic position" would alter significantly with favourable outcome/s from the multiple conversations with the fda in the next quarter.
feedback on assays for bla
pathways for heart failure and heart disease
and ghvd adults protocol
All those things in the next quarter sounds exciting.
Just one arising question though:
"Why are they wanting to raise all this money now, at record lows with all the associated dilutuon, instead of just waiting a few months until some of those "favourable outcomes" manifest themselves, and they would be able to raise capital at a higher price that reflects the significant change in the "strategic position"?
.
Ann: Information For Retail Shareholders, page-152
-
- There are more pages in this discussion • 390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.070(5.09%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.46 | $1.38 | $3.893M | 2.760M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 30663 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 3340 | 5 |
View Market Depth
| Last trade - 13.26pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |